The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities

Cells. 2023 Apr 23;12(9):1227. doi: 10.3390/cells12091227.

Abstract

Endometriosis is a chronic disorder of the female reproductive system which afflicts a great number of women worldwide. Histone deacetylases (HDACs) prevent the relaxation of chromatin, thereby positively or negatively modulating gene transcription. The current review aims at studying the impact of histone modifications and their therapeutic targeting in endometriosis. In order to identify relevant studies, a literature review was conducted using the MEDLINE and LIVIVO databases. The current manuscript represents the most comprehensive, up-to-date review of the literature focusing on the particular role of HDACs and their inhibitors in the context of endometriosis. HDAC1, HDAC2, HDAC3, Sirtuin 1, and Sirtuin 3, are the five most studied HDAC enzymes which seem to, at least partly, influence the pathophysiology of endometriosis. Both well-established and novel HDACIs could possibly represent modern, efficacious anti-endometriotic drug agents. Altogether, histone modifications and their therapeutic targeting have been proven to have a strong impact on endometriosis.

Keywords: deacetylase; endometriosis; histone; inhibitor; therapy.

Publication types

  • Review

MeSH terms

  • Endometriosis* / drug therapy
  • Female
  • Histone Code
  • Histone Deacetylase 1 / metabolism
  • Histone Deacetylase Inhibitors* / pharmacology
  • Histone Deacetylase Inhibitors* / therapeutic use
  • Histone Deacetylases / metabolism
  • Humans

Substances

  • Histone Deacetylase Inhibitors
  • Histone Deacetylase 1
  • Histone Deacetylases

Grants and funding

This research received no external funding.